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Purpose: Bisphosphonates relieve metastatic bone pain, prevent, reduce and delay skeletal morbidity in
metastatic bone disease and are recommended in European guidelines but safety concerns, speciﬁcally
renal dysfunction and osteonecrosis of the jaw, necessitate speciﬁc precautions when administered
intravenously. Pan-European guidance for nurses at the forefront of patient-focussed cancer care is
required to minimise patient risk.
Methods: A panel of urology and oncology nurses from seven European countries collaborated to decide
what constituted best practice for bisphosphonate administration when indicated for prevention of
skeletal-related events in patients with advanced urological malignancies.
Results: The panel agreed that urology, oncology, and home-care nurses who are at the forefront of
patient-focussed care are well placed to ensure best practice is followed but across Europe nurses have
insufﬁcient training on bisphosphonate administration for urological cancers. Based on extensive clinical
experience in administering bisphosphonates the panel propose best practice for identifying those
patients who could beneﬁt, for example those with bone pain or at risk of fracture, and for minimising
risk of adverse events by checking renal function, adjusting dosing, ensuring adequate hydration, and
regularly assessing dental health, as well as providing information and support.
Conclusions: Sharing this best practice across Europe could assist nurses who care for patients with
urological cancers and bone metastases or indeed those caring for cancer patients in general, to take the
lead, or at least be aware of what is the best practice that helps to ensure effective and safe IV
bisphosphonates administration to patients under their care.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Bone is an extremely common site of cancer metastases that
frequently causes pain and puts patients at risk of skeletal-related
events (SREs), including pathological fractures and spinal cordnsen), pascale.dielenseger@
(L. Drudge-Coates), kﬂynn@
w.de (S. Hieronymi), e.v.
voorzitter.urobel@telenet.be
Y-NC-ND license.compression (Wilkinson et al., 2008). Intravenous (IV) bisphosph-
onates have an accepted place in the management of bone
metastases in patients with advanced malignant neoplasms and
have been shown to decrease the prevalence and impact of cancer-
related skeletal complications (Aapro et al., 2008; Coleman, 2008;
Drake et al., 2008; Yuen et al., 2006). Although included as a valid
therapeutic option in various European guidelines (Bader et al.,
2009; Heidenreich et al., 2009; DGU, 2009), their use in clinical
practice may be tempered by safety concerns. In particular, risks for
patients with renal impairment and a much publicised association
with osteonecrosis of the jaw (ONJ) necessitate speciﬁc precautions
to be taken prior to their administration (Drake et al., 2008). The
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patients with urological malignancies, places urology, oncology and
home-care nurses at the forefront of patient-focussed care for
prostate, renal, and bladder cancer. However, across Europe as
a whole there is a wide variation in the role of nurses and in some
countries, the role is not as well developed or so clearly deﬁned as
in others.
It is against this background that a European panel of expert
urology and oncology nurses decided to review how closely
recommendations associated with IV administration of
bisphosphonates were followed in their clinics or in a home-care
setting, and to reach a consensus onwhat they thought constituted
best practicewhen administering these agents for the prevention of
SREs in patients with advanced urological malignancies metasta-
sising to bone. This best practice could potentially be applied to
other areas where administration of IV bisphosphonates may be
indicated, for example, in breast or lung cancer (Brown and
Coleman, 2002; Jahanzeb and Hirsh, 2010), or multiple myeloma
(Gralow, 2010), but due to the small sample sizes available for
studies in patients with multiple myeloma and some other solid
tumours (Fizazi et al., 2009) there is limited data available onwhich
to base practice advice. As the experience of the panel members is
primarily in the use of bisphosphonates for prevention of bone loss
and skeletal-related events in patients with advanced urological
cancers, this remained the focus of their review.Multidisciplinary team working for patients with urological
cancers
In 2002 the UK National Institute of Clinical Excellence (NICE)
published its Manual for Improving Outcomes in Urological Cancers
that recommended that all patients with urological cancers should
be managed by multidisciplinary urological cancer teams (NICE
2002). Because patient advocacy and the provision of information
and support for patients and caregivers are crucial aspects of their
role, NICE recommended that nurses should become the highly
skilled communicator within the team (NICE, 2002). As a conse-
quence, the role of the urology nurse specialist in the UK has
developed to the extent that in many centres, these highly speci-
alised nurses take a lead role in the care of men with urological
cancers including the provision of follow-up services for patients
with bone metastases.
Multidisciplinary team-working for urology services is also
established or advocated in other European countries. Nurse-led
follow-up clinics for patients with stable urological cancers are
common in Scandinavia with nurses monitoring disease markers
(for example, prostate speciﬁc antigen (PSA) levels), pain intensity,
and how well patients are coping with their cancer and its treat-
ment. These nurses act within a recognised framework which
allows them to recommend to the patient’s doctor when pain relief
is needed or that referral for a bone scan or magnetic resonance
imaging (MRI) may be necessary. Standards of care are maintained
due to a system of governance. Although the term ‘specialist nurse’
is not used in France, all French nurses involved in themanagement
of urological cancer patients have a level of expertise that
empowers them to take part in decision making processes related
to the care of their patients. The National Cancer Plan for France,
launched by President Chirac in 2002, and updated in 2009 (Le Plan
Cancer, 2009e2013) advocates collaboration for research efforts
and innovation, a better consideration of health inequalities for
patients facing cancer, and strengthening the coordination of new
health initiatives and medico-social care. French nurses are now
actively involved in providing information and support about
cancer and its treatment to patients and their caregivers.In Germany, nurses are beginning to take over some of the
traditional physicians’ responsibilities, for example, administering
intravenous (IV) medication. The German Society of Urology
(Deutsche Gesellschaft für Urologie e DGU) recently presented
a new interdisciplinary guideline for early detection, diagnosis, and
treatment of various stages of prostate cancer that encourages
multidisciplinary team-working (DGU, 2009). As the guideline is
relatively new it will take some time for interdisciplinary working
practices to become established. In the meantime, German nurses
involved in the care of patients who are prescribed IV bisphosph-
onates are still, often working independently from other disci-
plines, which makes it difﬁcult to implement common standards of
care for all patients.
In the Netherlands, specialized oncology nurses, urology nurses
and clinical nurse specialists/nurse practitioners are involved in the
care for prostate cancer patients in all phases of the disease. In the
multidisciplinary guideline for prostate cancer there is a special
place for nurses in providing education and psychosocial support.
The Health Care Inspectorate in the Netherlands has also made
a clear statement (Inspectie voor Gezondheidszorg, 2009) that
there is a strong need for a case manager for each cancer patient
and this is a role particularly suited to nurse specialists.
The Irish government established a National Cancer Control
Programme to look at issues affecting the care of oncology patients
in the Republic of Ireland and to encourage closer multidisciplinary
team-working. Within the Irish public health system, diagnostic
and surgical treatment centres have been opened or are in the
planning stages to cater for the needs of patients with prostate
cancer across the whole of Ireland. However, care of Irish patients
with prostate cancer may be managed by urologists, medical
oncologists, or radiation oncologists; within the public health
system or in the private sector. With neither standardised models
for multidisciplinary team-working, nor any formal requirement or
process for sharing case notes across Ireland, across specialities or
between health sectors, multidisciplinary team practice in Ireland
varies considerably.
Europe-wide initiatives are needed to encourage networking
and to educate, develop and implement standards for all nursing
specialities, but there is a clear role for urology or oncology nurses
to take the lead and ensure that patients with urological cancers
who are administered IV bisphosphonates, are informed and given
the support they need. The European Association of Urology Nurses
(EAUN) is keen to develop pan-European evidence-based guide-
lines for their nursing colleagues who are involved in urological
cancer care. An EAUN group for transrectal ultrasound (TRUS)
biopsy guidelines is already established and a series of guidelines
on various aspects of urological cancer care including one on bone
health, are planned. By developing guidelines, standardising best
clinical practice, and by working closely with other pan-European
nursing bodies, such as the European Oncology Nursing Society
(EONS) and patient groups, EAUN hopes to increase awareness of
what constitutes best practice to support and encourage urology
nurses to take a lead in improving quality of cancer care, particu-
larly for patients with urological cancers across Europe.
Urological cancers and bone health
Prostate cancer is the most common cancer in men in many
western countries; the crude annual incidence in the European
Union (EU) is 78.9/100,000 men and the mortality rate is 30.6/
100,000 men/year (Horwich et al., 2009). The crude incidence of
invasive bladder cancer in the EU is 19.5/100,000/year with 70% of
patients with bladder cancer over 65 years of age (Bellmunt et al.,
2009). Renal cell carcinoma accounts for 2e3% of all adult malig-
nancies; it is the seventh most common cancer in men and the
Table 1
Prevalence of metastatic bone disease.
5-year world prevalence
(thousands)a
Incidence of bone
metastases in cancers (%)b
Prostate 1555 65e75
Bladder 1000 40
Renal 480 20e25
Breast 3860 65e75
Lung 1394 30e40
Multiple
myeloma
144 70e95
Thyroid 475 60
Melanoma 533 14e45
a Parkin et al., 2001.
b Coleman, 2001.
Fig. 2. Pedicle screw ﬁxation of the spine. (Courtesy of L. Drudge-Coates: King’s
College Hospital, London.)
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urological tumour types the prevalence of metastatic bone disease
is highest in prostate cancer followed by bladder cancer, and then
renal cell carcinoma (Coleman, 2001; Parkin et al., 2001) (Table 1).
Metastatic bone disease disrupts the normal homeostasis of
bone; a resulting increased and unbalanced bone metabolism leads
to a loss of bone integrity, which is not without consequence. The
loss of bone integrity in patients with advanced cancer often results
in signiﬁcant skeletal morbidity, including bone pain, pathological
fractures, and occasionally spinal cord or nerve root compression
(Coleman, 2008) (Figs. 1 and 2).
Bone pain is themost prevalent of all cancer-associated pain and
is often accompanied by a substantial decline in patient-reported
quality of life (QoL) (Coleman, 2008). If a pathological fracture
occurs patients may require radiation to the bone or orthopaedic
surgery to prevent or repair structural damage. The risks of pain or
SREs due to fragile bones are an additional burden for patients with
advanced urological cancers that can seriously limit mobility and
contribute to deterioration in QoL and a loss of independence
(Coleman, 2008; Saad et al., 2004a) (Table 2).
Patients with advanced prostate cancer appear to have the
greatest propensity for bonemetastases of all the urological cancers
(Coleman, 2001; Yuen et al., 2006) and in more than 50% of men,
metastatic disease appears to be clinically conﬁned to bone
(Coleman, 2008). Not only does prostate cancer itself lead to a loss
of bone integrity but its treatment with androgen deprivationFig. 1. Metastatic renal cell carcinoma: vertebral collapse with subsequent spinal cord
compression. (Courtesy of L. Drudge-Coates: King’s College Hospital, London.)(hormone) therapy (ADT) also has profound effects on bone health
(Coleman, 2008).
Prior to treatment with ADT there is already a high prevalence of
osteoporosis in men with prostate cancer (Smith et al., 2001a,b);
this may be by virtue of their age, increasing frailty, or the physical
effects of the cancer itself. In addition, osteoporosis is of special
concern for men receiving ADT. The rate of bone loss in these men
seems to markedly exceed that associated with menopause in
women (Berruti et al., 2002). Annual bone mineral density losses of
0.6%e8% have been reported in patients treated with ADT, with the
most signiﬁcant loss within 12 months of starting treatment
(Holmes-Walker et al., 2006; Israeli et al., 2008). In a series of 395
men receiving ADT for prostate cancer 23% developed osteoporosis
and 7% non-pathologic fractures (Malcolm et al., 2007). The pres-
ence of bone metastases is considered a sign of therapeutic failure,
of hormone resistance, and of tumour progression (Gálvez et al.,
2008). In prostate cancer, nearly 20% of men surviving at least 5
years after diagnosis will have a fracture if treated with ADT,
compared with 12% of men not receiving ADT (Shahinian et al.,
2005). Health-economic modelling has also demonstrated that
the costs incurred from treating SREs in patients with metastatic
prostate cancer can be substantial (Felix et al., 2007). There is also
a chance that hypercalcaemia of malignancymay be precipitated by
hormonal therapy (Cancerweb, 2009; Coleman, 2008).Bisphosphonates in metastatic urological cancers
The goal of bisphosphonate therapy in patients with bone
metastases is to preserve functional independence and QoL by
preventing SREs and by controlling bone pain. A considerable body
of evidence supports the use of nitrogen-containing bisphospho-
nates (ibandronate, pamidronate, and zoledronic acid) in meta-
static cancer and bisphosphonates have been used over the last 15
years to improve outcomes of patients with bone metastases from
a variety of solid tumours (Aapro et al., 2008).
Bisphosphonates have been shown to prevent, reduce and delay
skeletal morbidity and complications associated with osteoporosis
and metastatic bone disease (Ross et al., 2004; Aapro et al., 2008).
The evidence base supporting the efﬁcacy is not the same for all
bisphosphonates as not all bisphosphonates administered intra-
venously to patients with advanced cancer (ibandronic acid,
Table 2
Bone-related events and functional consequences.
Bone related events
Pathologic fracture Radiation to bone Spinal cord compression Surgery to bone
Functional
consequences
Extended healing time;
50% never heala
Repeat daily clinic visits for
treatment of spinal cord compressiond
Excruciating paine Hospital admission
Surgical ﬁxation or prosthetic
replacementb
Myelosuppression,
pancytopenia, pneumonitisd
Irreversible paraparesis or
paraplegiaf, incontinencef
Risk of complications
from invasive technique
(e.g. wound breakdown,
stabilisation failure, infection,
excessive haemorrhage)f
Vertebroplasty or kyphoplastyc
Post-surgical external
beam radiationb
Chronic narcotic administration
for analgesia;
risk of associated side effectse
Delay in other treatments
(chemotherapy, radiotherapy)b
a Gainor and Buchert, 1983.
b Jacofsky and Haidukewych, 2004.
c Halpin et al., 2004.
d Smith et al., 1999.
e Coleman, 1997.
f Abrahm, 2004.
B.T. Jensen et al. / European Journal of Oncology Nursing 16 (2012) 42e53 45pamidronate, zoledronic acid) have been investigated for use in all
solid tumours; consequently there are differences in their approved
indications (Aapro et al., 2008; Morgan and Wagstaff, 2009)
(Table 3). Although orally administered clodronate is approved for
use in patients with breast cancer or multiple myeloma with
skeletal metastases, earlier generation (non-nitrogenous)
bisphosphonates are considered to be several orders of magnitude
less potent than the nitrogen-containing agents, and despite
a potential beneﬁt in preventing bone loss, several randomised
trials have failed to demonstrate statistically signiﬁcant beneﬁt
versus placebo in patients with bone metastases from prostate
cancer (Aapro et al., 2008; Saylor and Smith, 2010). In breast cancer
with bone metastases, for which there is clinical data for many of
the available agents, zoledronic acid demonstrated the greatest SRE
risk reduction of all bisphosphonates evaluated and signiﬁcantly
improved pain scores (Pavlakis et al., 2005; Major, 2007).
In patients with metastatic bone disease secondary to hormone-
refractory prostate cancer, zoledronic acid signiﬁcantly reduced the
ongoing relative risk of SRE by 36% (hazard ratio ¼ 0.640;
p ¼ 0.002) and delayed the ﬁrst SRE by more than 5 months
(p ¼ 0.009) compared with placebo (Saad et al., 2004b). In a study
in 40 patients with metastatic bladder cancer, zoledronic acid 4 mg
IV every 3e4 weeks reduced the risk of, and time to bone-related
event and improved 1-year overall survival compared with placebo
(Zaghloul et al., 2008). In a subset analysis of 74 patients with renal
cell carcinoma zoledronic acid 4 mg IV every 3 weeks also signiﬁ-
cantly reduced the mean skeletal morbidity rate and reduced the
risk of developing an SRE by 61% compared with placebo (hazard
ratio ¼ 0.394; p ¼ 0.008) (Lipton et al., 2003).
Studies have shown that pamidronate can prevent bone loss and
increase bone mineral density in the hip and spine in patients with
prostate cancer but how these effects translate to reductions inTable 3
Approved indications for bisphosphonates.
Indication
Breast
Cancer
Multiple
myeloma
Prostate
cancer
Renal, bladder,
other solid
tumours
Clodronate (oral) U U Not approved Not approved
Ibandronate (oral or IV) U Not approved Not approved Not approved
Pamidronate (IV only) UU UU Not approved Not approved
Zoledronic acid (IV only) UU UU UU UU
Adapted from Major et al. 2007.
U ¼ European registration only UU ¼Worldwide registration.skeletal morbidity in patients with metastases is uncertain (Brown
et al., 2004). Indeed combined analysis of two randomised placebo
controlled trials of pamidronate in metastatic prostate cancer
patients failed to demonstrate a signiﬁcant overall treatment
beneﬁt compared with placebo in palliation of bone pain or
reduction of SREs (Small et al., 2003). There are no published
studies to date that have demonstrated effect on reduction of SREs
following IV administration of ibandronic acid to urological cancer
patients although some preliminary data from small phase II
studies in metastatic prostate cancer is emerging (Morgan and
Wagstaff, 2009).
To date, there have also been no direct head-to-head studies
comparing bisphosphonates for the prevention of SREs in patients
with advanced prostate cancer, although pamidronate and zole-
dronic acid have been compared in patients with breast cancer or
multiple myeloma (Rosen et al., 2001, 2003). More recently, zole-
dronic acid has been compared to the monoclonal antibody
receptor activator of nuclear factor-kB ligand (RANKL) inhibitor,
denosumab, in a phase III study in 1901 men with bone metastasis
from castration-resistant prostate cancer; compared with zole-
dronic acid, denosumab signiﬁcantly delayed the time to ﬁrst on-
study SRE (median 20.7 months denosumab versus 17.1 months
with zoledronic acid: p ¼ 0.008) (Fizazi et al., 2010). Denosumab
has also been shown to be superior to zoledronic acid in delaying or
preventing SREs in patients with breast cancer metastatic to bone.
In a randomised, controlled study, time to ﬁrst SRE was delayed by
18% in patients receiving denosumab compared with zoledronic
acid (hazard ratio¼ 0.82, 95% CI 0.71e0.95, p¼ 0.01) (Stopeck et al.,
2010). Additionally, the risk of developing multiple SREs was
reduced by 23% compared with zoledronic acid (rate ratio 0.77, 95%
CI 0.66e0.89, p¼ 0.001) (Stopeck et al., 2010). A recent multicentre,
Phase III study demonstrated that denosumab was non inferior to
zoledronic acid in multiple myeloma (Henry et al., 2009). While
time to ﬁrst SRE or hypercalcaemia was signiﬁcantly greater with
denosumab compared with zoledronic acid (19.0 months versus
14.4 months, p ¼ 0.02), superiority was not achieved in terms of
time to ﬁrst SRE, or time to ﬁrst and second subsequent SRE
(p ¼ 0.06 and p ¼ 0.14, respectively). Denosumab was approved in
May 2010 for use in Europe for the treatment of bone loss associ-
ated with hormone ablation in men with prostate cancer at
increased risk of fractures, but is not licenced for the prevention of
SREs (EMA, 2010).
The use of bisphosphonates to relieve pain secondary to bone
metastases has also been the subject of systematic review (Wong
and Wiffen, 2002) although the mechanism by which bone pain
Table 4
Summary of criteria for identifying patients at risk of SREs.
EAU Guidelines on prostate cancer
A bone scan to detect presence of bone metastases is recommended if:
 Prostate speciﬁc antigen (PSA) >20 ng/ml
 Rate of change in prostate speciﬁc antigen (PSA velocity) >2 ng/ml/year
 Pain.
Heidenreich et al., 2009.
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prostate cancer patients have demonstrated reductions in pain
scores following IV administration of zoledronic acid, pamidronate,
and ibandronic acid (Saad, 2008) and have led to recommendations
that bisphosphonates should be considered for the treatment of
refractory bone pain due to metastases (Bader et al., 2009). Pre-
clinical studies also suggest that bisphosphonates may have direct
anti-tumour effects in prostate cancer (Saad, 2008) and a rando-
mised clinical trial (ZEUS) to determine whether zoledronic acid
can prevent bonemetastases in high risk prostate cancer patients is
currently on-going (Wirth et al., 2008). Encouraging data from
phase clinical III studies inmultiplemyeloma and breast cancer also
indicate that when used in combination with chemotherapy or
hormonal therapy, bisphosphonates such as zoledronic acid may
have positive beneﬁts on overall survival (Morgan et al., 2010),
disease free survival, or reduce tumour recurrence (Morgan et al.,
2010; Gnant et al., 2010). Gálvez et al. (2008) showed that by
effectively reducing pain with zoledronic acid, functional status
(mobility and QoL) was also improved.
Guidelines for bisphosphonate use in prostate cancer patients
The European Association of Urology (EAU) guidelines on
prostate cancer recommend that bisphosphonates may be offered
in the palliative management of hormone refractory patients who
present with skeletal masses, to prevent osseous complications
(Heidenreich et al., 2009).
The DGU guideline refers to the data for zoledronic acid (Saad
et al., 2004b, 2007), stating that in hormone refractory prostate
cancer with bone metastasis, only zoledronic acid in combination
with vitamin D and calcium showed a signiﬁcant reduction in SREs
compared with placebo. The DGU guideline recommends the use of
zoledronic acid to prevent SREs in all patients with metastasised
prostate cancer, even if they are symptom free.
Additionally, the DGU recommend bisphosphonates as an add-
on to other therapeutic options for pain relief (radiation or chemo-
therapy) in symptomatic patients with metastases. Similarly, NICE,
the British Association of Urological Surgeons (BAUS), the EAU, and
theEuropeanSociety forMedicalOncology (ESMO) recommend that
bisphosphonates may be considered for pain relief for men with
hormone-refractory prostate cancer when other treatments
(including analgesics and palliative radiotherapy) have failed (Bader
et al., 2009; Horwich et al., 2009; NICE and BAUS, 2009).
The Dachverband Osteologie (DVO), representing scientiﬁc
osteology societies of Germany, Austria, and Switzerland, has also
recently issued a guideline for the prevention, diagnosis and
treatment of osteoporosis in adulthood. The guideline recognises
the effects of ADT and advocates the use of bisphosphonates in all
prostate cancer patients who are under hormonal treatment and
have proven bone loss (DVO-Guideline, 2009).
In the authors experience, in current clinical practice
bisphosphonates are usually administered to patients with
advanced (castrate resistant) metastatic prostate cancer following
a rise in PSA, the presence of painful symptoms, or if a history of
pathologic fracture, impending fracture or spinal cord compression
is identiﬁed.
What is the best practice?
The authors, a panel of expert urology and oncology nurses from
seven European countries, originally met in spring 2009 at an
industry-sponsored advisory board meeting. The purpose of the
meeting was to evaluate the results of an internet-based survey of
the EAU membership about the use of bisphosphonates in prostate
cancer and to relate theﬁndings to their own experience. During thecourse of the meeting it became apparent that the members of the
advisory board felt that in Europe as a whole, not all patients who
might beneﬁt from bisphosphonates were identiﬁed, were indeed
prescribed bisphosphonates, and when they were, the precautions
for use were not necessarily followed or fully understood.
The consensus of the panel was that there was a lack of
education regarding the use of bisphosphonates in most of the
countries represented. As with many areas of nursing care there are
few randomised clinical trials that comprehensively support what
nurses do in practice, but the group as a whole had a wealth of
clinical experience from the day-to-day administration of IV
bisphosphonate formulations to patients with urological cancers.
After the meeting they collaborated to share their views on what
constituted best clinical practice for identifying patients at risk of
SREs, and for minimising risk to patients who are prescribed IV
bisphosphonates; this included advice about renal function testing
and dose modiﬁcation, ensuring adequate hydration, dental health
assessments, and how best to monitor those at risk, and to provide
information and support to patients. If asked to grade the evidence-
base for this best practice according to recommendations from the
Oxford Centre for Evidence-based Medicine (www.cebm.net), it
would be, by the very nature of how it has been derived, graded as
level IVc. Elements of this practice are based on consensus opinion,
case reports, literature reviews, and manufacturers’ recommenda-
tions, but in the main this best practice advice is based on the
extensive clinical experience of the panel.Identifying patients at risk of skeletal-related events
Due to improvements in the detection of prostate cancer, the
proportion of patients presenting with metastases at diagnosis has
drastically been reduced (Berruti et al., 2002). However, there are
no clear recommendations on how to identify those at risk of an
SRE and no accurate predictors that can identify those who might
beneﬁt from treatment with bisphosphonates.
The EAU guidelines recommend that patients who have a PSA
>20 ng/ml or a PSA velocity >2 ng/ml per year or pain symptoms
should have a bone scan (scintigraphy) to detect the presence of
bone metastases (Table 4); although the guidelines also state that
all patients with poorly differentiated tumours and locally
advanced disease should have a staging bone scan regardless of
their serum PSA value (Heidenreich et al., 2009). The Gleason score
and clinical staging at presentation correlate with subsequent
development of bone metastases (Ross et al., 2004), and therefore
a high Gleason score is also suggestive of the presence of bone
metastases. Elevations in bone markers, a history of SRE, or indi-
cation of a heavy skeletal load may also be useful indicators of risk.
Bone speciﬁc alkaline phosphatase and urinary N-telopeptide
(NTX), reﬂecting excessive bone turnover characteristic of osteo-
blastic bone metastases from prostate cancer, are being used to
diagnose bone metastases (Luz and Aprikian, 2010). However,
further research is needed to determine whether any biochemical
markers can predict prostate cancer bone metastasis (Zafeirakis,
2010). An abnormal PSA level or presence of pain appears to be
the only marker of treatment failure and disease progression
Table 5
Monitoring renal function and dose modiﬁcationa.
 Ensure blood creatinine and urea is measured 3e4 days prior to scheduled
infusion time
- if creatinine and urea increased ensure patient is adequately hydrated
- recommended intake is 1e2 L of ﬂuid in the 24 h preceding infusion.
 Do not give zoledronic acid if creatinine has increased by
- 0.5 mg/dl or 44 mmol/l for normal base-line creatinine (<1.4 mg/dl or
<124 mmol/l), or
- 1.0 mg/dl or 88 mmol/l for abnormal base-line creatinine (>1.4 mg/dl or
>124 mmol/l).
- Resume treatment at previous dose level if creatinine returns to within 10%
of baseline.
Adjust initial zoledronic acid dose prior to initiation of therapy in mild to
moderate renal impairment (CrCl 30e60 ml/min) according to the table
below:
Baseline Creatinine Clearance (ml/min) Recommended Dose of zoledronic acidb
>60 4.0 mg
50e60 3.5 mgb
40e49 3.3 mgb
30e39 3.0 mgb
<30 Not recommended
- If CrCl 30e90 ml/min increase infusion time to give 90 mg pamidronate dose
over 4 h
- If CrCl 30e50 ml/min increase infusion time to give 6 mg ibandronate dose
over 1 h
- Do not give pamidronate and zoledronic acid to patients with severe renal
impairment (CrCl <30 ml/min).
- The recommended dose and infusion time for ibandronate in severe renal
impairment is 2 mg given over at least 1 h.
a Information provided is consistent with the UK Summary of Product Charac-
teristics (SPC) for Aredia, and with the European SPCs for Bondronat and Zometa;
Note: pamidronate and ibandronate are not licenced for use in urological cancers.
b Doses have been calculated assuming target AUC of 0.66 (mg hr/l) (CrCl¼ 75ml/
min). The recommended dose should be given as an IV infusion over at least 15 min
every 3e4 weeks.
Table 6
Hydration.
- Ensure patient is adequately hydrated
- the recommended intake is 1e2 L of ﬂuid in the 24 h preceding infusion
- So for example can suggest patients drink at least 500 ml of ﬂuid at
home prior to coming to clinic, and at least 500 ml of ﬂuid during the
infusion time.
- Check patient for signs of dehydration (thirst, dry mouth, skin consistency)
- if signs of dehydration present, patients should be re-hydrated prior to
receiving the infusion (intravenously, if necessary).
 Avoid over-hydration in patients at risk of cardiac failure.
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investigation for the presence of bone metastases (Heidenreich
et al., 2009; DGU, 2009).
According to EAU guidelines, bone scintigraphy is not recom-
mended for the routine follow-up of asymptomatic patients, but
may be indicated in individuals with elevated PSA levels for whom
the ﬁndings will affect the treatment decision. It is also indicated in
patients with symptoms arising from the skeleton, since metastatic
disease may occur even if PSA is undetectable (Heidenreich et al.,
2009). However, skeletal scintigraphy lacks speciﬁcity for differ-
ential diagnosis of malignant versus benign processes (Heidenreich
et al., 2010). Imaging techniques such as MRIs or CT scans are
integral for diagnosis of metastatic urogenital cancer for staging as
well as for monitoring and following-up the effects of metastases
over time (Heidenreich et al., 2010). New scanning techniques, such
as whole-body (11)C-choline PET/CT have been shown to be
selectively useful for re-staging prostate cancer after early
biochemical relapse (Castellucci et al., 2011). However, the EAU
guidelines state CT or MRI have no place in the routine follow-up of
asymptomatic patients. A need to involve specialists in radiology,
radiation oncology, and nuclear medicine as well as those for
oncological urology to develop interdisciplinary consensus on
imaging has been recognised (Heidenreich et al., 2010).
Bone scans are not generally requested for hormonenaïve patients
and late presentation or late diagnosis of prostate cancer further
complicates identiﬁcation of patients at risk. However, diffusion
weighted (DW)magnetic resonance (MR) imaginghasbeensuggested
as a means of monitoring antiandrogen therapy in bone metastases
that is correlated to PSA level decrease (Reischauer et al., 2010).
Regular assessment of bone mineral density using Dual Energy
X-Ray Absoptiometry (DEXA) is also advocated to identify those
with bone density loss, osteopenia, or osteoporosis, and particu-
larly for those receiving long-term ADT (Heidenreich et al., 2009;
Liu et al., 2008). However, whether this advice is followed is
dependent upon access, who pays for it, and whether the cost is
reimbursable. There is considerable variation across Europe
depending on which speciality provides the service (e.g. oncology
or orthopaedic services); whether there are speciﬁc bone-health
clinics as well as how many centres have the appropriate equip-
ment and where it is geographically located. However, the use of
DEXA scans is questionable when bone metastases are known to be
present as the results are unreliable compared to other techniques,
such as quantitative computed tomography (Smith et al., 2001a,b)
or bone scintigraphy, PET-CT or whole body or axial skeleton MRI
(Heidenreich et al., 2010).
Further research is needed to provide nurses with better tools to
identify those patients at high risk of bone complications and to
predict those patients who might beneﬁt from bisphosphonate
treatment. A change in focus from one of reactivity to one when
there is a proactive approach to preventing bone loss may be
advantageous for patients but further data, including data on the
cost-effectiveness of the early identiﬁcation of patients and early
prevention strategies is needed to support this change.
Minimising risk to patients prescribed IV bisphosphonates
Who administers IV bisphosphonates, who pays for the associ-
ated treatment costs (primary or secondary care), as well as
competition with other specialties for clinic space for IV adminis-
tration procedures, affects both usage and safety.
In many European countries there is no specialist training
required for nurses to administer IV bisphosphonates, although
nurses are trained to administer IV medications and specialist
training is given to those that routinely administer chemotherapy.
Similarly, although the incidence of ONJ has beenwidely publicised,the precautions required to minimise the risk do not seem to be
generally advocated by non-specialist nursing staff.
During their spring 2009 meeting, the panel found that in
Belgium, The Netherlands, the UK, and Ireland, administration of IV
bisphosphonates was hospital based and as there was a certain
degree of competition between urology and oncology services for
space and stafﬁng for IV administration of drugs, it was not always
the urology nurse who administered treatment. In Denmark, IV
drugs are routinely administered at out-patient clinics close to the
patient so lack of clinic space was not an issue, although knowledge
about speciﬁc precautions associated with bisphosphonates was
variable. In France, bisphosphonates are not reimbursed if admin-
istered in the hospital setting, but France has a well-established
network of home-care nurses who administer a range of parenteral
drugs. A lack of speciﬁc knowledge about IV bisphosphonate
administration may also exist in Germany where since the cost is
reimbursed regardless of whether given in the hospital or in
a general practice setting, IV bisphosphonates are given by anyone
trained to give IV drugs. Given the diversity of expertise, speciﬁc
recommendations for IV bisphosphonates that could be widely
disseminated across Europe may help to minimise the risk of side
Fig. 3. Osteonecrosis of the jaw. (Courtesy of L. Drudge-Coates: King’s College Hospital,
London.)
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Best practice for minimising risk to patients prescribed IV
bisphosphonates from the individual panel members clinical
experience was consolidated and agreed, and is summarised below
and in the accompanying tables.
Monitoring renal function and dose modiﬁcation
Decreased renal function and renal toxicitymarked by an increase
in serum creatinine from baseline have been reported as adverse
events associated with the administration of bisphosphonates.
Dehydration, pre-existing renal impairment and long-term therapy,
particularly with IV administration, are factors that may increase the
potential for deterioration in renal function and for developing renal
toxicity (Berenson, 2005; Mortimer and Pal, 2010).
In 2005, the US and European product label for IV zoledronic
acid was updated to include additional renal safety precautions,
including dose adjustment in patients with mild to moderate renal
impairment. When initiating treatment in patients with metastatic
bone lesions from solid tumours, serum creatinine should be
determined, then the creatinine clearance (CrCl) should be deter-
mined. CrCl is calculated using the Cockcroft-Gault formula, and the
dose adjusted accordingly (Table 5).
Proactive monitoring of renal function is considered to be
essential and renal monitoring guidelines have also been estab-
lished to minimise the risk of renal deterioration during
bisphosphonate therapy (Berenson, 2005; Mortimer and Pal, 2010).
Similar precautions and patient monitoring requirements also
apply to the administration of pamidronate and ibandronate
(Berenson, 2005) (Table 5). Ensuring that patients are adequately
hydrated can help reduce the risk to renal function (Table 6).Table 7
Frequency of ONJ in patients with malignant bone disease treated with bisphosphonates
Study Study type P
b
Hoff et al. (2008) Chart review 3
Durie et al. (2005) Web-based survey 1
Pozzi et al. (2007) Chart review
Badros et al. (2006) Chart review/observational
Tosi et al. (2006) Retrospective review of
trial database
Dimopoulos et al. (2006) Chart review
Cafro et al. (2005) Chart reviewPrevention and management of osteonecrosis of the jaw
Osteonecrosis of the jaw (ONJ), a painful area of necrotic exposed
bone in themouth that fails to heal (Fig. 3), is an uncommon adverse
event, which has been reported in oncology patients receiving
bisphosphonates to prevent SREs (Van den Wyngaert, 2007; Wang
et al., 2007; Grewal and Fayans, 2008; Sambrook et al., 2008; Gebara
and Moubayed, 2009). Depending on the study population, the
administered drug and its dose, and the method used to collect the
data, the reported incidence of ONJ associated with bisphospho-
nates (Table 7), mostly derived from retrospective analyses (Woo
et al., 2006), ranges from 0.7% to 12.6%.
Patients with ONJ present with a spectrum of symptoms, signs,
and severities ranging from relatively asymptomatic to more severe
(Ruggiero et al., 2006). Symptoms include localised pain, soft tissue
swelling, exudation (discharge of pus), loose teeth, bad breath,
a numb or heavy jaw and changes in sensitivity. Objective signs upon
presentation include a sudden change in the health of periodontal or
mucosal tissues (ulcers, exposed areas of bone), failure of themucosa
to heal, soft-tissue infection, loose teeth, or undiagnosed oral pain
(Ruggiero et al., 2006; Bagán et al., 2007). Bone scintigraphy andMRI
changes may detect ONJ before clinical symptoms appear but may
also mimic metastatic disease ﬁndings so these techniques are not
currently used routinely to monitor patients for ONJ (Krishnan et al.,
2010). Bone biopsy can conﬁrm ONJ but should only be performed if
metastatic disease is suspected (Ruggiero et al., 2006). Fistulae to
maxillary antrum or nose and on rare occasions to the ear, patho-
logical fracture or osteolysis may also develop. If ONJ is suspected,
radiological imaging should be used to rule out other causes but the
radiologic signs are those consistent with changed density of the
bone and bone loss (Ruggiero et al., 2006). The exact aetiology of ONJ
is still unclear; however concomitant risk factors including tooth
extractions (in about 60% of cases), ill-ﬁtting dentures, and invasive
dental surgery during the course of therapy, as well as type of
bisphosphonate, dose, and duration of therapy appear to be impor-
tant factors (Woo et al., 2006). ONJ appears to occur more frequently
in patients receiving IV than oral bisphosphonates and seems to be
more frequently associated with use in patients with cancer (King
and Umland, 2008); up to 13% incidence following IV administra-
tion in cancer patients compared with less than 1% following oral
administration for osteoporosis (Edwards et al., 2008; Ruggiero et al.,
2009). Previous invasive dental treatment, for example, tooth
extraction, has been identiﬁed as the most predominant inciting
event for ONJ, but in many of the reported cases patients had also
been receiving treatment with chemotherapeutic agents or corti-
costeroids. Development of local infection, including osteomyelitis
may also be implicated (Woo et al., 2006; Pazianas et al., 2007; King
and Umland, 2008).
Reports of ONJ are not restricted to use of bisphosphonates;
there have been reports of ONJ following the use of denosumab
(Fizazi et al., 2010; Stopeck et al., 2010) as well as with some of the
newer anti-angiogenics, bevacizumab and sunitinib, when used in: prior to implementation of prevention strategies.
atients treated with
isphosphonates (n)
Suspected or
proven ONJ (n)
Frequency (%)
994 29 0.7%
203 152 12.6%
888 16 1.8%
340 11 3.2%
259 9 3.5%
202 15 7.4%
118 14 11.9%
Table 8
Prevention and management of ONJ.
- Recommend that those scheduled for IV bisphosphonates
- visit a dentist prior to starting treatment for the ﬁrst time to check
dental health (a ‘dear dentist’ letter explaining the reason for referral
may be helpful)
- complete any dental treatment required prior to starting bisphosphonate
therapy.
- Remind patients to maintain good oral hygiene throughout treatment.
- Check for signs associated with developing ONJ regularly
- has the patient noticed bad breath, gum swelling, any loose teeth or needed
to visit their dentist recently.
Table 9
Managing acute phase reactions and other side effects.
- Acute-phase reactions (transient fever, muscle and joint aches,
headache, chills)
- recommend antipyretics (e.g. 1 g paracetamol four times daily unless
contraindicated)
- Nausea, vomiting, loss of appetite
- ask doctor to prescribe metoclopramide, or domperidone (according to local
guidelines or preferences).
- Blood and laboratory abnormalities
- ensure anaemia is treated according to Hb level, symptoms, and local
guidelines
- hypophosphatemia and hypocalcaemia do not usually require treatment as
generally asymptomatic. However, calcium and vitamin D supplements are
recommended for all patients receiving IV bisphosphonates to minimise
risk of hypocalcaemia and to ensure adequate intake to help prevent
osteoporotic bone loss.
- Skin or eye reaction like redness, pruritus or conjunctivitis
if minor but worrisome skin emollients, anti-histamines, or ophthalmic
preparations (e.g. non-steroidal anti-inﬂammatory eye drops) may be
recommended or prescribed.
if reactions are severe more aggressive treatment with corticosteroids may
be necessary
Table 10
Communicating with patients during IV administration.
- Ask the patient whether there has been any change in how they feel since
last visit
- check for side effects of bisphosphonate therapy
- check symptoms of progressive disease (e.g. voiding problems,
haematuria, pain or neurological symptoms) and refer patient to
clinician if any cause for concern
- Discuss speciﬁc recommendations about possible side effects and how they
might be minimised
- ensure patient has access to appropriate medication
- give patient contact details for hospital or tell them to consult a GP if
symptoms are severe or prolonged.
- Ensure that patients are given an appointment for the next infusion
- Ensure patients have access to appropriate treatment between appointments
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cancer types (Greuter et al., 2008; Estilo et al., 2008; Aragon-Ching
et al., 2009; Brunello et al., 2009). In denosumab phase III studies,
osteonecrosis of the jaw occurred in 22 (2.3%) denosumab treated
patients with castration-resistant prostate cancer with bone
metastases compared with 12 (1.3%) patients treated with zole-
dronic acid (p ¼ 0.09) whilst among 2046 patients with advanced
breast cancer, ONJ was reported in 20 (2%) treated with denosumab
compared to 14 (1.4%) treated with zoledronic acid (p ¼ 0.39)
(Fizazi et al., 2010; Stopeck et al., 2010).
As with the recognition of renal safety issues, the US and
European labels for bisphosphonates were amended in 2005 to
draw attention to the possible association of their administration
and ONJ and for all cancer patients prescribed bisphosphonates to
receive a dental examination prior to initiation of therapy, to have
regular dental check-ups, and to avoid dental surgery wherever
possible (FDA, 2005; EMA 2009). In 2009 the European Medicines
Agency (EMA) Committee for Medicinal Products for Human Use
(CHMP) completed a review of the risk of ONJ. In their conclusion,
the EMA reiterated the recommendations for patients, dentists and
prescribers to help protect against the risk of ONJ, and called for
appropriate action to be taken across Europe (EMA, 2009). These
regulatory announcements and recommendations have been
echoed by various professional bodies on both sides of the Atlantic.
Several professional bodies (Khan et al., 2008; IMB, 2010) including
the European Association of Urology (Bader et al., 2009) and
various dental associations (Edwards et al., 2008; Ruggiero et al.,
2009; Rogers et al., 2010) have issued guidance for proactive
monitoring, prevention andmanagement of ONJ. Patients who have
developed ONJ should be referred to an oral maxillofacial surgeon
or dental oncologist. Conservative management with antibiotics,
superﬁcial debridement, and maintaining good dental hygiene is
recommended (Migliorati et al., 2006; Bagán et al., 2007; Ruggiero
et al., 2009). Areas of exposed bone may beneﬁt from protection
with a removable appliance and it should be noted that whenever
possible, unless ONJ is severe, non-surgical approaches to
encourage wound healing are preferred.
If patients with cancer are referred for dental assessment to
ensure that any dental treatment is completed before they start
therapy with bisphosphonates, and are encouraged to maintain
good oral hygiene during treatment, then ONJ is both preventable
and manageable if it occurs (Ripamonti et al., 2009; Dimopoulos
et al., 2009).
In cancer patients with solid tumours with bone metastases
exposed to zoledronic acid, the incidence of ONJ decreased from
7.8% to 1.7% following implementation of dental preventive
measures (Ripamonti et al., 2009) whilst Dimopoulos et al. (2009)
found a signiﬁcant almost three-fold decrease after implementing
preventive measures in patients with multiple myeloma treated
with zoledronic acid. For patients receiving bisphosphonate
therapy antibiotic prophylaxis after an invasive dental treatment
is recommended to reduce the risk of ONJ (Montefusco et al.,
2008; Kyrgidis and Andreadis, 2008). Wound healing beforebisphosphonates are administered is essential. Given the relevant
beneﬁts of bisphosphonates in the prevention of bone metastases-
related SREs, the prevention and treatment of ONJ is of great
importance. The panel’s consolidated best practice (Table 8) was
based on evidence based guidance issued by various regulatory
authorities and professional bodies.
Managing acute-phase reactions and other commonly reported side
effects
Up to 55% of patients administered bisphosphonates intrave-
nously for the ﬁrst time may commonly experience all or some of
the symptoms (transient fever, muscle and joint aches, headache,
or chills) characteristic of an acute phase systemic inﬂammatory
reaction. For example, fever and arthralgias has been reported in
14% of prostate cancer patients receiving pamidronate during
androgen-deprivation therapy (Smith et al., 2001a,b); and fever in
21% of men with hormone-refractory prostate cancer and bone
metastasis and in 55% of women with metastatic breast cancer
treated with zoledronic acid (Saad et al., 2002; Kohno et al., 2005).
These generally self-limiting symptoms can usually be managed
with supportive and symptomatic treatment with agents such as
NSAIDS and paracetamol, and tend to resolve completely within
24e48 h (Tanvetyanon and Stiff, 2006; Drake et al., 2008)
(Table 9).
Although the main focus of the panel was a discussion of best
practice for minimising the risk of problems associated with renal
dysfunction and development of ONJ, other side effects that have
been associated with bisphosphonates that are worthy of mention
Fig. 4. Example of questionnaire for use by nursing staff. (Courtesy of L. Drudge-Coates, King’s College Hospital, London and B. Turner, Homerton University Hospital, London.)
B.T. Jensen et al. / European Journal of Oncology Nursing 16 (2012) 42e5350include nausea, vomiting, and loss of appetite (although more
commonly associated with oral administration), anaemia, hypo-
phosphatemia, hypocalcaemia, and skin and uncommonly eye
symptoms, redness, pruritus or conjunctivitis (Tanvetyanon andStiff, 2006). Recent studies have suggested a link between the use
of IV bisphosphonates and subsequent development of atrial
ﬁbrillation, and although further evidence is needed to conﬁrm
this, nursing staff should be aware of this possibility (Wilkinson
B.T. Jensen et al. / European Journal of Oncology Nursing 16 (2012) 42e53 51et al., 2010; Gralow, 2010). As with acute phase reactions, if nursing
staff are aware of these other side effects they can be managed
appropriately (Table 9) and the risk of serious adverse events will
remain relatively low.
Communicating with patients
IV administration of bisphosphonates facilitates contact time
with patients and an increased opportunity for urology, oncology,
out-patient, and home-care nurses to take the lead in ensuring
a patient-focussed service for patients receiving treatment
(Table 10).
Before and during the infusion is a good opportunity to talk with
patients not only about their treatment but also about physical,
psychological, and social aspects of their cancer. As many patients
are very sick and perhaps also receiving chemotherapy, time in
clinic also presents as opportunity to discuss various issues with
accompanying relatives and carers.
A questionnaire given to patients, whilst they wait in clinic or
have their infusion, could help facilitate communication, and help
to highlight potential problems that could then be proactively
managed. This questionnaire could evaluate whether the patient
had experienced chills, fever or muscle and limb pain following
infusion; voiding problems; pain; neurological symptoms such as
reduced leg strength or numbness; teeth or jaw problems; or any
other discomfort.
A similar type of questionnaire might also be used by nursing
staff to document changes in pattern of pain, relevant blood
chemistry, any history of falls or fractures, dental health, previous
or concurrent use of chemotherapy, as well as any reported side
effects associatedwith bisphosphonate administration (an example
of such a questionnaire can be seen in Fig. 4).
Implications for practice e the role of nurses
Although bisphosphonates are widely given, there seems still be
a lack of education regarding side effects andmonitoring. All efforts
should be made to prevent, recognize, and effectively manage
potential complications, including identifying patients reporting
bone pain, treating acute phase reaction symptoms, monitoring
renal function, hydrating patients and repleting calcium, and
encouraging gooddental health. Sharing best practice across Europe
could assist those who routinely administer IV bisphosphonates
ensure that these agents areboth effectivelyand safelyadministered
to patients with urological cancers and bonemetastases. Whilst the
authors recognise that it may not be easy for nurses to take the lead
to incorporate these suggestions for best practice into their daily
clinical practice, all nurses who care for patients with urological
cancers should be aware of what constitutes best practice and strive
to ensure that their clinical practice is evidence based. Further
research is needed to provide nurses with better tools to identify
those patients at high risk of bone complications, to predict those
patients who might beneﬁt from bisphosphonates, and the optimal
time to start treatment. A change in focus from one of reactivity to
onewhen there is a proactive approach to preventing bone lossmay
be advantageous for patients but further data, including data on the
cost-effectiveness of the early identiﬁcation of patients and early
prevention strategies is needed to support this change. However,
this panel of experiencednurses hope that by sharing their expertise
nurses who come into contact with patients with metastatic
urological cancers, and indeed any patient for whom IV
bisphosphonate treatment is indicated, will be encouraged to
become more involved with identifying patients at risk of SREs and
in ensuring that when IV bisphosphonates are prescribed they are
administered appropriately.Conﬂict of interest
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